Isomorphic Labs secures $2.1 billion Series B, cementing AI drug-discovery leadership

Isomorphic Labs announced on Tuesday that it has closed a $2.1 billion Series B financing round.

The sizable round underscores the company’s position as a bellwether for using artificial intelligence in drug discovery, a strategy the firm has championed since its inception.

With this capital infusion, the raise becomes the second‑largest private biotech financing in history, highlighting strong investor confidence in AI‑driven approaches to developing new medicines.